Physician profile
John D Olkowski
NPI 1396897427
$14,914.51
in general payments reported to CMS, 2019-2025
27 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $30.06 · 2021: $313 · 2022: $904 · 2023: $1,203 · 2024: $255 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,900 · Food and Beverage: $2,534 · Travel and Lodging: $2,495 · Long Term Medical Supply Or Device Loan: $838 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,900.00 |
| Food and Beverage | $2,534.19 |
| Travel and Lodging | $2,494.89 |
| Long Term Medical Supply Or Device Loan | $838.09 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $10,120.62 | 2022-2025 | Epioxa, Travoprost Intraocular Implant - Idose, Kxl System |
| Alcon Vision LLC | $1,477.27 | 2019-2025 | Unity, Argos, Clareon Panoptix Pro |
| Dompe US, INC. | $537.15 | 2019-2025 | Oxervate |
| Kowa Pharmaceuticals America, INC. | $282.10 | 2022-2023 | Seglentis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $275.15 | 2019-2021 | |
| Oyster Point Pharma, INC. | $273.59 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $254.22 | 2019-2025 | Cequa, Xelpros |
| Rxsight INC | $215.99 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Johnson & Johnson Surgical Vision, INC. | $206.90 | 2019-2025 | Tecnis Iol, Lipiflow System Activator (Disposable) |
| Mallinckrodt Hospital Products INC. | $187.89 | 2020-2023 | Acthar |
| Sight Sciences, INC. | $135.38 | 2022 | |
| Amgen INC. | $124.41 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $108.18 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $105.81 | 2022-2023 | Vyzulta, Toric, Miebo |
| Horizon Therapeutics Plc | $96.27 | 2023 | Tepezza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $73.96 | 2019-2023 | |
| Quidel Corporation | $66.75 | 2019 | |
| Harrow Eye, LLC | $61.93 | 2023-2025 | Iheezo, Vevye |
| Eyevance Pharmaceuticals LLC | $56.77 | 2019 | |
| Abbvie INC. | $55.53 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $54.31 | 2021 | |
| Allergan, INC. | $33.89 | 2019-2022 | |
| Shire North American Group INC | $32.54 | 2019 | |
| Biotissue Holdings INC. | $29.59 | 2025 | |
| Mallinckrodt Enterprises LLC | $21.40 | 2019 | |
| Optos, INC. | $15.88 | 2019 | |
| Omeros Corporation | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Olkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.